Luc Dirix

37.2k total citations · 3 hit papers
311 papers, 14.6k citations indexed

About

Luc Dirix is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luc Dirix has authored 311 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 227 papers in Oncology, 102 papers in Cancer Research and 95 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luc Dirix's work include HER2/EGFR in Cancer Research (68 papers), Cancer Treatment and Pharmacology (56 papers) and Breast Cancer Treatment Studies (51 papers). Luc Dirix is often cited by papers focused on HER2/EGFR in Cancer Research (68 papers), Cancer Treatment and Pharmacology (56 papers) and Breast Cancer Treatment Studies (51 papers). Luc Dirix collaborates with scholars based in Belgium, United States and United Kingdom. Luc Dirix's co-authors include Steven Van Laere, Peter A. van Dam, Peter Vermeulen, Peter Vermeulen, Ilse Van der Auwera, Cécile Colpaert, Eric A. Van Marck, Gert G. Van den Eynden, Eric Van Marck and Ina Benoy and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Luc Dirix

307 papers receiving 14.3k citations

Hit Papers

Phase III Study of Bevacizumab Plus Docetaxel Compared Wi... 2010 2026 2015 2020 2010 2017 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2010 700 citations Luc Dirix, Joohyuk Sohn et al. Journal of Clinical Oncology profile →
  2. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
    2017 581 citations Luc Dirix, Guy Jérusalem et al. Breast Cancer Research and Treatment profile →
  3. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
    2017 429 citations Luc Dirix, Patrick Schöffski et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luc Dirix Belgium 65 9.4k 4.6k 4.4k 3.4k 1.4k 311 14.6k
Suzette Delaloge France 56 8.4k 0.9× 5.0k 1.1× 3.4k 0.8× 3.8k 1.1× 1.6k 1.1× 399 13.9k
Sabino De Placido Italy 64 7.8k 0.8× 3.7k 0.8× 4.4k 1.0× 4.5k 1.3× 1.6k 1.2× 381 14.0k
Angelo Di Leo Italy 62 9.9k 1.1× 5.2k 1.1× 4.1k 0.9× 4.5k 1.3× 1.7k 1.2× 313 14.4k
Ahmad Awada Belgium 61 9.5k 1.0× 3.0k 0.6× 5.2k 1.2× 4.8k 1.4× 1.5k 1.0× 542 16.2k
P. Fumoleau France 61 9.6k 1.0× 4.4k 1.0× 3.3k 0.7× 2.7k 0.8× 2.3k 1.6× 326 14.3k
Alberto Ocaña Spain 51 7.3k 0.8× 2.5k 0.5× 3.8k 0.9× 2.5k 0.7× 1.7k 1.2× 302 12.3k
Joan Albanell Spain 56 7.9k 0.8× 3.0k 0.6× 4.8k 1.1× 2.9k 0.9× 2.4k 1.7× 251 12.6k
Patrice Viens France 61 10.5k 1.1× 5.6k 1.2× 6.0k 1.3× 2.8k 0.8× 704 0.5× 353 17.5k
Young‐Hyuck Im South Korea 51 8.7k 0.9× 3.8k 0.8× 2.9k 0.7× 3.7k 1.1× 2.5k 1.8× 270 12.4k
Stefan Sleijfer Netherlands 61 7.1k 0.8× 3.5k 0.8× 4.2k 1.0× 4.7k 1.4× 667 0.5× 379 13.6k

Countries citing papers authored by Luc Dirix

Since Specialization
Citations

This map shows the geographic impact of Luc Dirix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luc Dirix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luc Dirix more than expected).

Fields of papers citing papers by Luc Dirix

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luc Dirix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luc Dirix. The network helps show where Luc Dirix may publish in the future.

Co-authorship network of co-authors of Luc Dirix

This figure shows the co-authorship network connecting the top 25 collaborators of Luc Dirix. A scholar is included among the top collaborators of Luc Dirix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luc Dirix. Luc Dirix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Walker, John, Célèste Lebbé, Giovanni Grignani, et al.. (2020). Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. Journal for ImmunoTherapy of Cancer. 8(1). e000313–e000313. 52 indexed citations
2.
Iwase, Toshiaki, Kenichi Harano, Hiroko Masuda, et al.. (2020). Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 20(1). 430–430. 6 indexed citations
3.
Stremitzer, Stefan, Peter Vermeulen, Mark Kockx, et al.. (2020). Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. British Journal of Cancer. 122(10). 1518–1524. 31 indexed citations
4.
Sharma, Padmanee, Joohyuk Sohn, Sang Joon Shin, et al.. (2019). Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Clinical Cancer Research. 26(1). 61–70. 34 indexed citations
5.
Bertucci, François, Pascal Finetti, Arnaud Guillé, et al.. (2019). NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers. Molecular Oncology. 14(3). 504–519. 27 indexed citations
6.
Beije, Nick, Wendy Onstenk, Jaco Kraan, et al.. (2016). Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia. 18(11). 647–653. 40 indexed citations
7.
Fontein, D.B.Y., Mia Klinten Grand, J.W.R. Nortier, et al.. (2015). Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial. Annals of Oncology. 26(6). 1254–1262. 29 indexed citations
8.
Saura, Cristina, Johanna C. Bendell, Guy Jérusalem, et al.. (2014). Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. Clinical Cancer Research. 20(7). 1935–1945. 110 indexed citations
9.
Dirix, Luc, et al.. (2013). Trastuzumab emtansine in breast cancer. Expert Opinion on Biological Therapy. 13(4). 607–614. 5 indexed citations
10.
Woodward, Wendy A., Savitri Krishnamurthy, Hideko Yamauchi, et al.. (2013). Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Research and Treatment. 138(3). 761–772. 41 indexed citations
11.
Peeters, Dieter, Pieter‐Jan van Dam, Annemie Rutten, et al.. (2013). Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. British Journal of Cancer. 110(2). 375–383. 59 indexed citations
12.
Bertucci, François, Naoto T. Ueno, Pascal Finetti, et al.. (2013). Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of Oncology. 25(2). 358–365. 77 indexed citations
13.
Vergote, Ignace, Agustin A. García, John P. Micha, et al.. (2013). Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer. Journal of Clinical Oncology. 31(32). 4060–4066. 34 indexed citations
14.
Cardoso, Fátima, Jean‐Luc Canon, Dino Amadori, et al.. (2012). An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. The Breast. 21(6). 716–723. 12 indexed citations
15.
Bartlett, John M.S., Cassandra Brookes, Tammy Robson, et al.. (2011). Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology. 29(12). 1531–1538. 142 indexed citations
16.
Dam, Peter van, et al.. (2011). Are Costs of Robot-Assisted Surgery Warranted for Gynecological Procedures?. Obstetrics and Gynecology International. 2011. 1–6. 35 indexed citations
17.
Tabernero, Josep, Luc Dirix, Patrick Schöffski, et al.. (2011). A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(19). 6313–6321. 46 indexed citations
18.
19.
Eynden, Gert G. Van den, Marcel Smid, Steven Van Laere, et al.. (2008). Gene Expression Profiles Associated with the Presence of a Fibrotic Focus and the Growth Pattern in Lymph Node–Negative Breast Cancer. Clinical Cancer Research. 14(10). 2944–2952. 23 indexed citations
20.
Laere, Steven Van, Tim Beißbarth, Ilse Van der Auwera, et al.. (2008). Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer. Clinical Cancer Research. 14(22). 7452–7460. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suzette Delaloge Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Angelo Di Leo Breakdown of academic impact, for papers by Ahmad Awada Breakdown of academic impact, for papers by P. Fumoleau Breakdown of academic impact, for papers by Alberto Ocaña Breakdown of academic impact, for papers by Joan Albanell Breakdown of academic impact, for papers by Patrice Viens Breakdown of academic impact, for papers by Young‐Hyuck Im Breakdown of academic impact, for papers by Stefan Sleijfer
Rankless by CCL
2026